Currently available GLP-1 receptor agonists in the UK include: Exenatide (short-acting and extended-release formulations) - licensed for type 2 diabetes Liraglutide (once-daily injection) - licensed for type 2 diabetes (Victoza) and separately for weight management (Saxenda 3mg) Dulaglutide (once-weekly injection) - licensed for type 2 diabetes, including cardiovascular risk reduction in those with established cardiovascular disease or multiple risk factors Semaglutide (once-weekly injection and oral formulation) - licensed for type 2 diabetes (Ozempic, Rybelsus) and separately for weight management (Wegovy 2.4mg) A related but distinct medication is tirzepatide (once-weekly injection), which is a dual GIP/GLP-1 receptor agonist licensed for type 2 diabetes management
Medicare is a health insurance program in the US for people age 65 or older and younger people with disabilities
LSN3160440 is a positive allosteric modulator of the GLP-1R optimized to increase the affinity and efficacy of GLP-1(9-36), a proteolytic product of GLP-1(7-36)
c) coupling, optionally protected Aib and His amino acid, d) acylating an epsilon amino group of lysine residue in semapeptide with an acylating agent of Formula (V), which is optionally activated, In an aspect of fourth embodiment, optionally protected Aib is selected from Fmoc-Aib-OH and optionally protected His amino acid is selected from Boc-His(Boc)-OH
[PMID: 3975907] PubMed record related to this compound for laboratory literature review